Sagimet Biosciences Inc. Series A financials
$9.33−6.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.0M |
| Gross profit | $0.00 | $0.00 | $2.0M |
| Gross margin | — | — | 100.0% |
| Operating income | -$56.9M | -$54.5M | -$30.7M |
| Net income | -$51.0M | -$45.6M | -$27.9M |
| Net margin | — | — | −1393.8% |
| Diluted EPS | $-1.58 | $-1.45 | $-2.66 |
| EBITDA | -$56.9M | -$54.5M | -$30.7M |
| Operating cash flow | -$45.6M | -$42.4M | -$23.8M |
| Free cash flow | -$45.6M | -$42.4M | -$23.8M |
| Diluted shares | 32.3M | 31.4M | 10.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $35.0M | $75.8M | $75.1M |
| Short-term investments | $78.1M | $75.4M | $19.8M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $116.5M | $160.3M | $96.7M |
| Total liabilities | $5.1M | $4.5M | $5.7M |
| Shareholders' equity | $111.4M | $155.8M | $91.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology